In their first conference call with investors, PacBio's new CEO and CFO laid out a strategic plan for the company as it weathers the COVID-19 pandemic.
Though Guardant and Foundation have pioneered a path through the FDA for liquid biopsy tests, label differences highlight complex choices for oncologists.
The funds will support continued growth in precision oncology, new product development, and new initiatives in the clinical trial and biopharmaceutical markets.
The findings demonstrate the value of multi-cohort platform trials as an option for refractory cancer patients with particularly rare genomic tumor alterations.
Under the agreement, Intermountain will be able to implement Kailos' PGxComplete next-generation sequencing methodology in its laboratory for pharmacogenetic testing.
Sema4 will use its genomics testing abilities and Centrellis health intelligence platform to identify eligible patients for Janssen's oncology clinical trials.
The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.
GeneDx will provide whole-exome and whole-genome sequencing, among other services, to neonatal intensive care units staffed with Pediatrix-affiliated doctors.
The immune sequencing firm also provided an update on the development of its ImmunoSeq Dx clinical product for detecting prior infection with SARS-CoV-2.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
